ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARIA Ariad Pharmaceuticals, Inc.

23.99
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ariad Pharmaceuticals, Inc. NASDAQ:ARIA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 23.99 23.80 22.88 0 01:00:00

ARIAD to Webcast Conference Call on First Quarter 2016 Financial Results

26/04/2016 12:35pm

Business Wire


Ariad (NASDAQ:ARIA)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Ariad Charts.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2016 financial results on Tuesday, May 10, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.

The live webcast can be accessed by visiting the investor relations section of the Company’s website at http://investor.ariad.com. The call can be accessed by dialing 888 311-8173 (domestic) or 330-863-3376 (international) five minutes prior to the start time and providing the pass code 84030796. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an orphan oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat orphan cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

ARIAD Pharmaceuticals, Inc.For InvestorsMaria Cantor, 617-621-2208Maria.cantor@ariad.comorFor MediaLiza Heapes, 617-621-2315Liza.heapes@ariad.com

1 Year Ariad Chart

1 Year Ariad Chart

1 Month Ariad Chart

1 Month Ariad Chart

Your Recent History

Delayed Upgrade Clock